French biopharmaceutical company Transgene has randomised its first patient in the multiple-dose cohort of its Phase I/Ib trial of TG1050 to treat chronic hepatitis B virus (HBV) infection.

TG1050 has been developed as a targeted immunotherapy candidate indicated for the treatment of chronic hepatitis B, based on a viral vector expressing three HBV antigens.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Hepatitis B is a malignant liver infection caused by HBV infection, which can result in chronic infection and liver disease.

The condition can lead to death from cirrhosis of the liver and liver cancer if left untreated.

"TG1050 has been developed as a targeted immunotherapy candidate indicated for the treatment of chronic hepatitis B, based on a viral vector expressing three HBV antigens."

The Phase I/Ib trial is a first-in-man study conducted as an international, randomised, multi-centre, double-blind, placebo-controlled study.

See Also:

It is intended to evaluate TG1050 in patients who are currently undergoing treatment for chronic HBV infection with standard-of-care anti-viral therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study is primarily focused on assessing the safety and tolerability of TG1050 while being administered in single and multiple doses, as well as determining the dose and schedule of the immunotherapy candidate for further development.

The secondary goals of the study are to determine the antiviral activity of and immune responses triggered by TG1050.

TG1050 has demonstrated its efficacy in inducing robust, broad and long-lasting HBV-specific T-cells, as well as exhibiting its anti-viral effects such as seroconversion to the surface antigen (HBsAg).